Recurrence After Treatment of Cutaneous Basal Cell and Squamous Cell Carcinomas in Patients Infected With Human Immunodeficiency Virus

Hausauer, Amelia K.; Maurer, Toby; Leslie, Kieron; Parvataneni, Rupa; Stuart, Sarah; Chren, Mary‐Margaret

doi:10.1001/2013.jamadermatol.245

Cited by 30 publications

(20 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Immunochemotherapy has significantly improved outcome in the HIV-negative setting, and a number of reports suggest that the overall risk of CNS relapse has decreased with the addition of rituximab to CHOP chemotherapy [83][84][85] although this has not been detected in all reports [86]. This observation supports the hypothesis that CNS relapse is less likely to occur if there is improved control of systemic disease.…”

Section: Prevention Of Secondary Cns Lymphomamentioning

confidence: 81%

“…In the pre-HAART era, several chemotherapeutic agents (bleomycin, vinblastine, vincristine and etoposide) were shown to have activity against KS in case series and small Phase II trials using different combinations and doses of these drugs [84][85][86][87][88]. However, liposomal anthracyclines and taxanes have become established as the backbone of current standard systemic cytotoxic therapy against KS.…”

Section: Cytotoxic Chemotherapymentioning

confidence: 99%

“…Squamous cell carcinoma may present atypically, at a younger age, at unusual not classically sun-exposed cutaneous sites (e.g., the nail fold), affect the mouth, genitalia and perineum, and be multifocal and aggressive with a high risk of recurrence and metastasis with a high mortality [82][83][84][85][86].…”

Section: Skin Cancermentioning

confidence: 99%

“…Infundibulocystic, micronodular neurotropic and morpheiform variants, and even metastatic basal cell carcinoma have been reported. Generally, basal cell carcinoma was not thought to behave more aggressively in the HIV-infected population [87][88][89] but consensus is changing [86,90,91].…”

Section: Skin Cancermentioning

confidence: 99%

See 3 more Smart Citations

British HIV Association guidelines for HIV‐associated malignancies 2014

et al. 2014

View full text Add to dashboard Cite

Section: Prevention Of Secondary Cns Lymphomamentioning

confidence: 81%

Section: Cytotoxic Chemotherapymentioning

confidence: 99%

Section: Skin Cancermentioning

confidence: 99%

Section: Skin Cancermentioning

confidence: 99%

See 2 more Smart Citations

British HIV Association guidelines for HIV‐associated malignancies 2014

et al. 2014

View full text Add to dashboard Cite

“…Standart eksizyon 5 yıllık rekürrens oranlarının %2-10 arasında değiştiği bütün primer BHK olgularda etkili tedavi seçeneğidir [20][21][22] . Genel kabul gören güvenli cerrahi sınır 3-5 mm.…”

Section: Bhk Tedavi Seçenekleri Ve Güncel Yaklaşımlarunclassified

Current Advances in the Treatment of Basal Cell Carcinoma

Çalış¹,

Uzun²

2016

Acta Oncol Tur.

View full text Add to dashboard Cite

ÖZETBazal hücreli karsinom, derinin en sık görülen malign tümörü olup insidansı giderek artmaktadır. Predispozan faktörler arasında en önemlisi güneş ışınlarına maruz kalmaktır. Bununla birlikte genetik hastalıklar, organ nakilleri ve immünsupresyon da bazal hücreli karsinom gelişimini tetiklemektedir. Oldukça nadir metastaz yapmasına rağmen lokal agresif seyreder. Ana tedavi şekli cerrahi olup cerrahiye aday olmayan hastalarda radyoterapi, kriyoterapi, kemoterapi ve hedgehog yolak inhibitörleri kullanılabilir. Bu derlemede bazal hücreli karsinomun tedavisi konusunda güncel gelişmeler tartışılmıştır.Anahtar Kelimeler: bazal hücreli karsinom, cerrahi, vismodegib ABSTRACT Basal cell carcinoma is the most commonly seen malignant tumor of the skin and its incidence is gradually increasing. Sun exposure is the single most important predisposing factor. In addition, genetic disorders, organ transplantations and immunesupression may trigger the development of basal cell carcinoma. Although it metastasizes rarely, its clinical course is local aggressive. The main treatment modality is surgery. In patients who are not candidates for surgery; radiotherapy, cryotherapy, chemotherapy and hedgehog pathway modulators can be used. In this review, current advances in the treatment of basal cell carcinoma is discussed.

show abstract

Association of Multiple Primary Skin Cancers With Human Immunodeficiency Virus Infection, CD4 Count, and Viral Load

et al. 2017

View full text Add to dashboard Cite

IMPORTANCEPersons with human immunodeficiency virus (HIV) have a 2.8-fold higher risk than HIV-uninfected persons of nonmelanoma skin cancer (NMSC), defined as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Individuals with a prior NMSC history are at increased risk for subsequent NMSC, but the magnitude of risk and its relation to HIV disease-related factors, including CD4 count and viral load (VL), are unknown. OBJECTIVE To better understand how laboratory markers currently used to evaluate HIV disease progression may be associated with subsequent NMSC risk. DESIGN, SETTING, AND PARTICIPANTSThis cohort study analyzed 455 HIV-infected and 1945 HIV-uninfected patients, all of them members of the Kaiser Permanente Northern California (KPNC) health care plan, diagnosed with at least 1 NMSC from 1996-2008 to determine risk of subsequent NMSCs in relation to CD4 count and VL. All participants were white, non-Hispanic persons 18 years or older who had had at least 1 NMSC during the 1996-2008 period. Participants entered the cohort at their first NMSC diagnosis and were observed through 2008. Incidence rates were calculated and adjusted hazard ratios were estimated using extended Cox regression models with recent CD4 count and VL analyzed as time-changing covariates.MAIN OUTCOMES AND MEASURES Measured CD4 count, VL, and subsequent NMSC (BCC and SCC). RESULTSThe cohort comprised 455 HIV-infected participants (13 [3%] women) and 1952 HIV-uninfected participants (154 [8%] women). Median duration of observation was 4.6 years, and 16.5% (n = 390) either died (n = 35) or lost KPNC membership status (n = 355) without having a subsequent primary NMSC. Compared with HIV-uninfected persons, HIV-infected individuals were slightly younger (mean age, 52.5 vs 55.5 years), more likely men (97% vs 92%), more likely to have smoked (57% vs 45%), and less likely to be overweight/obese (50% vs 61%). The small observed differences by HIV status in matching characteristics (ie, age and sex) resulted from the restriction of the original cohort to those with at least 1 NMSC. Compared with uninfected individuals, those with HIV infection with a recent biomarker of more severe immune deficiency (CD4 count <200 cells/mL) had a 44% increased risk of subsequent NMSC overall and a 222% increase risk of SCC in particular, suggesting that subsequent SCC risk is associated with immune dysfunction.CONCLUSIONS AND RELEVANCE HIV-infected persons compared with HIV-uninfected persons were are at higher risk for subsequent new SCC but not BCC, with a dose-response relationship between risk and lower CD4 counts and higher VLs. Subsequent new primary SCCs had a strong association with lower CD4 and higher VL among HIV-infected persons, suggesting that immune dysfunction might contribute to increased SCC risk. Clinical implications include targeted monitoring for SCC among HIV-infected individuals, particularly those with low CD4 counts or high VLs.

show abstract

Recurrence After Treatment of Cutaneous Basal Cell and Squamous Cell Carcinomas in Patients Infected With Human Immunodeficiency Virus

Cited by 30 publications

References 11 publications

British HIV Association guidelines for HIV‐associated malignancies 2014

British HIV Association guidelines for HIV‐associated malignancies 2014

Current Advances in the Treatment of Basal Cell Carcinoma

Association of Multiple Primary Skin Cancers With Human Immunodeficiency Virus Infection, CD4 Count, and Viral Load

Contact Info

Product

Resources

About